跳至主要内容
临床试验/ISRCTN52272621
ISRCTN52272621已完成不适用

The B- VAX Project: providing hepatitis B vaccinations through assertive outreach to people who inject drugs

The Burnet Institute (Australia)0 个研究点目标入组 150 人开始时间: 2012年9月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Participants who are at risk of contracting HBV (or those not already immune or infected), will be identified from existing Burnet Institute cohort studies and approached to participate.

排除标准

  • Participants from Burnet Institute Cohort studies who are vaccinated or immune to HBV.

研究者

发起方
The Burnet Institute (Australia)

相似试验

已完成
不适用
Therapeutic vaccination for chronic hepatitis B virus infection in Africa
ISRCTN67270384niversity of Oxford (UK)77
进行中(未招募)
1 期
A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccinatioong-term protection against HBV infectionMedDRA version: 20.0Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)System Organ Class: 100000004848
EUCTR2020-000126-26-FIMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc200
进行中(未招募)
1 期
VACCINATION ADJUVED AGAINST HEPATITIS B IN SACYL WORKERS TYPED AS NO RESPONDERS TO CONVENTIONAL VACCINES
EUCTR2016-004991-23-ESIBSAL (Instituto de Investigación Biomédica de Salamanca)-Fundación Instituto de Estudios de Ciencias de la Salud de47
已完成
不适用
A randomised trial of hepatitis B booster vaccination at the age of 13 to 15 years following infant vaccination to assess efficacy against hepatitis B infection and acute hepatitisHepatitis B
ISRCTN71271385Medical Research Council (MRC) (UK)500
已完成
不适用
The Efficacy of Hepatitis B Virus (HBV) Vaccination in Patients with Previously Resolved HBV Infection Receiving Immunosuppressive Therapy to Prevent HBV Reactivation through Increase of Serum Levels of Anti-HBs (Pilot Study)Collagen disease, collagen disease related disease, ulcerative colitis, Crohn&#39s disease, intestinal Behcet&#39s disease (simple ulcers included), psoriasis, and diseases that require other immunosuppressive therapies.
JPRN-UMIN000042288Saitama Medical University13